Healthcare entity
All 3 tracked stories fall under one category: regulation. KPV is most often covered alongside BPC-157, which appears in 3 of these 3 stories. The 6 average consequence score is above the beat benchmark of 5.9 in the same window.
Last mentioned: Aug 1, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 3 tracked stories fall under one category: regulation. KPV is most often covered alongside BPC-157, which appears in 3 of these 3 stories. The 6 average consequence score is above the beat benchmark of 5.9 in the same window. Source depth averages 2.3 original sources per story, versus 2.5 across the same-window beat baseline. This profile follows 3 Healthcare stories mentioning KPV across the period from July 27, 2026 to August 1, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 54 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering KPV. Shared-story counts are live from our verified record — not editorial picks.
PCAC Votes to Recommend Six Peptides
The committee votes to recommend BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax for inclusion on the 503A Bulks List, culminating the multi-day review.
FDA PCAC Public Meeting Begins
The Pharmacy Compounding Advisory Committee commences a two-day meeting to review nominations of bulk drug substances, including six peptide candidates, for the 503A Bulks List.
A key FDA panel vote could expand legal access to BPC-157, TB-500, and four other peptides through compounding pharmacies. Vanta is positioning its telehealth and pharmacy network to deliver these therapies to consumers seeking longevity care.
An FDA advisory committee voted 8-6 to recommend allowing pharmacy compounding of unapproved peptides like BPC-157, raising urgent questions about patient safety, telehealth marketing practices, and regulatory integrity.
Source: santafenewmexican.com · texarkanagazette.com
A narrow FDA advisory panel vote to ease peptide compounding restrictions could trigger a rapid expansion of telehealth-delivered wellness treatments, despite a stark lack of safety data. With HHS Secretary RFK Jr. supporting access, healthcare providers must prepare for a new era of direct-to-consumer peptide therapies.
KPV is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
